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Defects in the human ferrochelatase gene lead to the
hereditary disorder of erythropoietic protoporphyria.
The clinical expression of this autosomal dominant
disorder requires an allelic combination of a disabled
mutant allele and a low-expressed nonmutant allele.
Unlike most other erythropoietic protoporphyria
populations, mutations identi®ed among Swiss ery-
thropoietic protoporphyria families to date have
been relatively homogenous. In this study, genotype
analysis was conducted in seven Swiss erythropoietic
protoporphyria families, three carrying mutation
Q59X, two carrying mutation insT213, and two
carrying mutation delTACAG580±584. Three different
haplotypes of ®ve known intragenic single nucleotide
polymorphisms, namely ±251 A/G, IVS1±23C/T, 798
G/C, 921 A/G, and 1520C/T, were identi®ed. Each
haplotype was shared by families carrying an identi-
cal mutation in the ferrochelatase gene indicating a
single mutation event for each of the three muta-
tions. These mutations have been present in the
Swiss erythropoietic protoporphyria population for a
relatively long time as no common haplotypes of
microsatellite markers ¯anking the ferrochelatase
gene were found, except of two conserved regions,
telomeric of the insT213 allele and centromeric of
the delTACAG580±584 allele, each with a size > 3 cM.
Among the nonmutant ferrochelatase alleles, patients
from six erythropoietic protoporphyria families
shared a common haplotype [±251G; IVS1±23T] of
the ®rst two single nucleotide polymorphisms. An
exception was the haplotype [±251 A; IVS1±23C]
identi®ed in the index patient of one erythropoietic
protoporphyria family. These results supported the
recent ®ndings that the low expressed allele is tightly
linked to a haplotype [±251G; IVS1±23T] of two
intragenic single nucleotide polymorphisms in the
ferrochelatase gene. Key words: ferrochelatase/founder
effect/intragenic SNP/recurrent mutation. J Invest
Dermatol 117:1521±1525, 2001
E
rythropoietic protoporphyria (EPP, MIM 177000) is a
genetic disorder of porphyrin metabolism caused by a
partial de®ciency of ferrochelatase activity.
Ferrochelatase (FECH; EC 4.99.1.1), the last enzyme
of the heme biosynthetic pathway, catalyzes the
insertion of Fe2+ ion into protoporphyrin IX to form heme
(Kappas et al, 1995). Defective ferrochelatase leads to the
accumulation of protoporphyrin IX, and occurs mainly in the red
blood cells. Clinically, an excess amount of free protoporphyrin
deposited in the skin causes an extremely painful photosensitivity in
EPP patients that starts in early childhood. In addition to cutaneous
photosensitivity, a small percentage (<2%) of patients develop
hepatobiliary complication as a result of the toxic effect of
protoporphyrin on the liver (Bloomer et al, 1998).
The human FECH gene localized on chromosome 18q contains
11 coding exons and has a size of approximate 45 kb; the entire
cDNA as well as partial genomic sequences have been published
(Nakahashi et al, 1990; Whitcombe et al, 1991; Taketani et al,
1992). Mutations in the human FECH gene have been shown to be
associated with the decrease in ferrochelatase activity in EPP. To
date, over 60 different FECH gene mutations have been published
in EPP patients from various countries and ethnic backgrounds
(Schneider-Yin et al, 2000a). The majority of the mutations are
family speci®c with a few exceptions of mutations being shared by a
limited number of EPP families. In Ireland, a single base pair
deletion (delG40) was identi®ed in three EPP families (Todd et al,
1993). In the U.S.A, mutations K379X and IVS1 + 5, g®a (del
exon 1), were each shared by four EPP families (Wang et al, 1999).
In Switzerland, recurrence of FECH gene mutations seems to be a
rather frequent phenomenon. In the past, we have identi®ed a total
of ®ve different mutations in the FECH gene of 13 Swiss EPP
families. Four of them, namely mutations Q59X, insT213,
delTACAG580±584, and del TG899±900, were found in more than
one apparently unrelated family (RuÈfenacht et al, 1998a).
Interestingly, mutation delTACAG580±584 has also been detected
in EPP patients from France and the U.S.A. (Bloomer et al, 1998;
RuÈfenacht et al, 1998a).
In general, molecular defects underlining EPP are heteroge-
neous, although mutations identi®ed among patients with liver
complications share a common feature of producing a truncated
enzyme. These so-called ``null allele'' mutations consist of frame-
shifts and nonsense mutations. The association between null allele
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mutations and liver complications in EPP is statistically signi®cant,
p < 0.05 (Schneider-Yin et al, 2000a).
The heredity of EPP has a complex pattern and cannot be simply
de®ned as either autosomal dominant or autosomal recessive
inheritance. In the majority of EPP families, a single mutation is the
only identi®able molecular defect in the FECH gene. Among all
carriers of a FECH gene mutation, less than 10% of the individuals
will develop the clinical symptoms of EPP, the majority remaining
asymptomatic throughout their lives. Various studies have shown
that, at the level of enzyme activity, symptomatic patients will
exhibit a value 10%±30% of normal, whereas asymptomatic carriers
will have approximately 50% of normal enzyme activity (Deybach
et al, 1986; Norris et al, 1990). The recent work by Gouya and
colleagues has led to the disclosure of the low expression
mechanism ± a step forward towards the understanding of the
low clinical penetrance in EPP (Gouya et al, 1996; 1999). Among
the patients of EPP families they studied, those with lower than
50% of normal ferrochelatase activity resulted from a reduced
mRNA transcription of the nonmutant FECH allele. Two single
nucleotide polymorphisms, ±251 A/G in the promoter region and
IVS1±23C/T, have been shown to be tightly linked to the low
expressed FECH allele (Gouya et al, 1999).
To explore the unique feature of recurrent FECH gene
mutations in the Swiss EPP population, haplotype analyses using
both intragenic single nucleotide polymorphisms (SNP) and
microsatellite markers were conducted among seven EPP families
carrying three frequent mutations. The data obtained from this
study indicated common ancestral alleles for each of the three
mutations, Q59X, insT213, and delTACAG580±584. In addition,
the role of two intragenic SNP (±251 A/G and IVS1±23C/T) on
the clinical penetrance of EPP was examined in this EPP cohort.
MATERIALS AND METHODS
Patients and specimens A total of 31 individuals from seven
unrelated Swiss EPP families, including 11 patients, 11 asymptomatic
mutation carriers, and nine healthy individuals, were studied. Peripheral
blood samples were collected from these individuals with informed
consent. The study design was approved by the ethical committee of
Stadtspital Triemli, ZuÈrich.
Mutations in the FECH gene Among the seven EPP families, three
families (I, II, and III) carried mutation Q59X, two families (IV and V)
carried mutation insT213, and two families (VI and VII) carried
mutation delTACAG580±584 in the FECH gene, as was previously
published (Schneider-Yin et al, 1994, 1995; RuÈfenacht et al, 1998a, b).
Table I. Haplotypes of the mutant FECH alleles among patients and asymptomatic carriers from EPP families
Locusa
Family
Q59X ins T213 delTACAG580±584
I II III IV V VI VII
D18S69 (0.78; 60.67 cM) 3 4 2 3 3 2 2
D18S1152 (0.80; 62.20 cM) 5 5 4 4 1,4 4 4
D18S41 (0.77; 62.76 cM) 2 2 2 4 2 2 2
D18S858 (0.77; 62.91 cM) 5 4 5 5 3 6 6
±251 A/G (promoter) G G G A A A A
IVS1-23 C/T (intron 1) T T T C C C C
798 G/C (exon 7) C C CG G G C C
921 G/A (exon 9) GA G G G G A A
1520 C/T (3¢-UTR) C C C C C C C
D18S381 (0.62; 63.80 cM) 6 6 4 4 4 3 2
D18S977 (0.91; 64.93 cM) 2,6 6 6 1 1 6 6
D18S1144 (0.85; 65.27 cM) 8 8 7,12 10 10 10 7
D18S1155 (0.67; 65.58 cM) 1 1,4 3 4 4 4 4
D18S64 (0.74; 67.28 cM) 5 3 4 4 3,4 5 5
aMarker order, heterozygosity, and marker distance were obtained from both LDB and GDB (see Materials and Methods). Heterozygosity and map position (cM) are given
in parentheses. The FECH gene is located at 63.76 cM.
Figure 1. Analyses of ®ve intragenic SNP in
the FECH gene. SNP ±51 A/G in the promoter
region, ±23C/T in intron 1, and 798 G/C in
exon 7 were analyzed by PCR ampli®cation of
genomic DNA and subsequent restriction enzyme
analyses using AluI, Cac81, and NlaIII,
respectively. SNP 921 A/G in exon 9 and 1250
C/T in the 3¢-UTR were analyzed by PCR
ampli®cation of genomic DNA, followed by
DGGE analysis.
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Intragenic SNP in the FECH gene Five known intragenic SNP in
the human FECH gene, namely ±251 A/G in the promoter region,
IVS1±23C/T, 798 G/C in exon 7, 921 A/G in exon 9, and 1520C/T
in the 3¢-UTR, were analyzed in all members of the seven EPP families.
In addition, ±251 A/G and IVS1±23C/T were determined in 32 control
samples.
Genomic DNA was isolated from peripheral blood of all subjects using
a QIAamp Blood kit (Qiagen, Germany). To analyze ±251 A/G, the
promoter region of the FECH gene was ampli®ed by using a sense
primer 5¢-CCG TCC CTC CAA GAA ATG and an antisense primer
5¢-GGT GTC CGC CCA GCA GTG. The 574 bp product was
digested with restriction enzyme Alu I (Boehringer Mannheim,
Germany). Partial sequence of intron 1 was ampli®ed by using a sense
primer 5¢-TTA CCT GCC TGC AGA GAA ATC A and an antisense
primer 5¢-GCT GGG CTG TTT CTG TGG TG for determination of
IVS1±23C/T. The 235 bp product was digested with restriction enzyme
Cac8 I (New England Biolabs, U.K.). Conditions for polymerase chain
reaction (PCR) ampli®cations of exon 7 and 9 of the FECH gene and
the subsequent denaturing gradient gel electrophoresis (DGGE) analysis
of exon 9 have been previously described (RuÈfenacht et al, 1998a).
Following the PCR, the 220 bp product of exon 7 was digested with
restriction enzyme Nla III (New England Biolabs). All enzyme digests
were analyzed in a 3% agarose gel. The 3¢-UTR of the FECH gene was
ampli®ed by PCR using primers as described by Gouya et al (1996). The
PCR product was analyzed by DGGE on a D GENE System (Bio-Rad,
Hercules, CA) with a linear denaturant gradient of 13%±43%. The
DGGE gel (16 3 16 cm) was run at 60°C for 3 h under a constant
voltage of 120 V.
Microsatellite markers ¯anking the FECH gene In addition to the
intragenic SNP, a total of nine microsatellite markers were selected for
haplotype analysis. Most of the microsatellites were chosen from the
Marsh®eld map (Broman et al, 1998) for maximum informativity. These
markers and additional polymorphisms are located in the genomic region
of the FECH gene in the order of cen±D18S69±D18S1152±D18S41±
D18S858±FECH±D18S381±D18S77±D18S1144±D18S1155±D18S64±qter
in the LDB map (Collins et al, 1996). The marker heterozygosities and
marker distances are given in Table I. PCR primers were either
purchased (Research Genetics, Huntsville, AL) or synthesized with the
available sequence information. PCR was performed using standard
conditions. After a 5 min heat denaturation at 95°C, the PCR products
were separated on 4%±6% (depending on the size of the alleles)
polyacrylamide sequencing gels of 17 3 50 cm (BioRad, Hercules, CA)
under a constant power of 50 W for 1.5±2.5 h (depending on the size of
the alleles). DNA fragments were visualized by silver staining (Haider et
al, 2000). Arbitrary numbers were assigned to different alleles in the
analyzed population, beginning with the largest allele.
RESULTS
Characterization of intragenic SNP Allelic characterization
of ®ve SNP in the FECH gene is shown in Fig 1. A 574 bp DNA
fragment in the promoter region bearing the A/G dimorphism at
position ±251 was ampli®ed by PCR. The presence of A or G at ±
251 position was veri®ed by Alu I digestion of the PCR product.
Homozygous A/A appeared as three bands of 379 bp, 153 bp, and
42 bp, whereas homozygous G/G appeared as two bands (421 and
153 bp) on the agarose gel. The C/T dimorphism at position ±23
near the intron 1±exon 2 junction was characterized by Cac 8I
digestion of PCR-ampli®ed genomic DNA. The PCR product
was cut into three fragments of 117 bp, 108 bp, and 10 bp in the
case of homozygous C/C, and was cut into two fragments of
225 bp and 10 bp in the case of homozygous T/T. A 220 bp
fragment spanning over exon 7 of the FECH gene was subjected to
Nla III digestion to determine the status of 798 G/C dimorphism.
The 220 bp fragment remained intact if a G was present on both
alleles. The presence of C at position 798 introduced a Nla III site.
The PCR product from a C/C homozygote was therefore digested
into two fragments of 127 bp and 93 bp by the enzyme.
SNP 921 A/G and 1520 C/T, located in exon 9 and the 3¢-
UTR of the FECH gene, respectively, were characterized by
DGGE analysis. As shown in Fig 1, both 921 G/G and A/A
Table III. Distribution of GT and AC haplotypes among




[±251 G; IVS1±23T] [-251A; IVS1±23C]
Patients (n = 11) 10 1
Carriers (n = 11) 0 11
Controls (n = 64)a 13/13 51/51
aAmong 32 control samples, analysis of both FECH alleles resulted in the identi-
®cation of an equal number (13) of Gs at ±251 and Ts at IVS1 ±23, and an equal
number (51) of As at ±251 and Cs at IVS1 ±23.
Figure 2. Haplotype analysis among Swiss EPP families using
intragenic SNP of the FECH gene. Patients, asymptomatic carriers,
and normal individuals are indicated by solid, half-®lled, and empty
symbols, respectively. The FECH gene alleles carrying a disabling
mutation are drawn in a rectangular frame. The alleles that are
responsible for the disease onset are in bold and italic. The SNP
positions at which all available members of a pedigree are heterozygous
are indicated by a question mark.
VOL. 117, NO. 6 DECEMBER 2001 HAPLOTYPE ANALYSIS OF SWISS EPP FAMILIES 1523
homozygotes appeared as a single band, but with different
migration rates in the DGGE gel. The A/G heterozygote showed
a characteristic pattern of quadruple bands in the gel. In the case of
the 1520 C/T dimorphism, the C/T heterozygote exhibited a
pattern of double bands, whereas the single bands from both C/C
and T/T homozygotes differed by their migration rates in the
DGGE gel.
Haplotype analysis using intragenic SNP Mutations in the
FECH gene of symptomatic patients among seven EPP families
were identi®ed by previous sequencing analysis (Schneider-Yin et
al, 1994, 1995; RuÈfenacht et al, 1998a). Other family members
were screened for the family-speci®c mutation by either DGGE or
restriction analyses to identify asymptomatic mutation carriers
(RuÈfenacht et al, 1998a, b). The statuses of patient, carrier, and
unaffected family member are indicated in the pedigrees in Fig 2.
Based on this information, haplotypes featured by ®ve intragenic
SNP were de®ned in ®ve pedigrees according to Mendelian
inheritance. In families I and III, however, 798 G/C could not be
aligned with other markers because all tested individuals from these
families were heterozygous G/C.
As presented in Fig 2, among all 62 alleles from 31 tested
individuals, including patients, carriers, and healthy relatives of the
seven EPP families, ±251 A was found invariably in cis to IVS1±
23C, and ±251G was at all times in cis to IVS1±23T.
The mutant FECH allele Haplotypes of the mutated FECH alleles
from the seven EPP families carrying three different FECH
mutations are illustrated separately in Table I. Each of the three
mutations was found to cosegregate with one particular haplotype
of the ®ve intragenic SNP in all families carrying the respective
mutations. Families I, II, and III, carrying the Q59X mutation,
shared a common haplotype of [G-T-C-G-C]. Families IV and V,
both carrying the insT213 mutation, shared a common haplotype
of [A-C-G-G-C]. Families VI and VII, both carrying the
delTACAG580±584 mutation, shared a common haplotype of [A-
C-C-A-C].
The nonmutant FECH allele As, as stated above, the nonmutant
FECH allele determines the clinical outcome of EPP, haplotypes of
patients were compared with those of the asymptomatic carriers. As
shown in both Fig 2 and Table II, the nonmutant FECH allele in
10 EPP patients from six families exhibited a common haplotype of
[±251G; IVS1±23T] at the ®rst two SNP. Only one patient in
family V showed a haplotype of [±251 A; IVS1±23C] in the
nonmutant FECH allele. In contrast, the nonmutant FECH allele
of all 11 asymptomatic carriers in this study cohort featured the
haplotype [±251 A; IVS1±23C] (Fig 2, Table III).
Haplotype analysis using microsatellite markers
The mutant FECH allele As described above, genotype analysis
using intragenic SNP indicated identical haplotypes for the three
most common FECH gene mutations in Switzerland. To further
investigate this phenomenon, nine microsatellite markers were
analyzed in all members of the seven EPP families. The
microsatellites ¯ank the FECH gene on chromosome 18q22 and
span »6.6 cM. In general, the results showed that no extended
conserved haplotypes were associated with the FECH gene
mutations in the analyzed genomic areas except for two regions.
As shown in Table I, one conserved telomeric region of the
insT213 allele spans »3.5 cM; the other conserved centromeric
region of the delTACAG580±584 allele spans »3.1 cM.
The nonmutant FECH allele Various haplotypes in the extended
genomic regions were observed among the seven nonmutant alleles
from EPP patients (Table II). In particular, no apparent similarities
were found among the six microsatellite haplotypes (from families I
to VI) that were linked to the common intragenic SNP haplotype
of [±251G; IVS1±23T].
DISCUSSION
Based on the available genetic information, mutations in the human
FECH gene are typically heterogeneous or family speci®c. Among
the few exceptions, mutations in the Swiss EPP families have been
found to be relatively homogenous (Schneider-Yin et al, 1994,
1995; RuÈfenacht et al, 1998a, b). In this study, we carried out
genotype analysis in order to test the hypothesis that families
carrying an identical FECH mutation are derived from a common
ancestor. This hypothesis was veri®ed insofar as an intragenic SNP
haplotype was conserved among analyzed patients, providing
evidence for a single mutation event for each of the three FECH
gene mutations in the Swiss population. In addition, two conserved
areas, telomeric of the insT213 allele and centromeric of the
delTACAG580±584 allele, were identi®ed by analyses of extragenic
polymorphisms covering a genomic region of 6.6 cM ¯anking the
FECH gene. No conserved microsatellite haplotypes were found to
be associated with any of the three mutations, however. Although
these results do not allow an accurate calculation of the age of the
mutations, it is reasonable to conclude that these recurrent FECH
gene mutations have been present in the Swiss EPP population for a
relatively long time.
Recurrent mutations or ``founder effects'' have been observed in
other disease-associated populations in Switzerland. Molecular
studies of the porphobilinogen deaminase gene unveiled a common
mutation of W283X, with a prevalence of around 60%, among
Swiss patients with acute intermittent porphyria (Schneider-Yin et
al, 2000b; Schuurmans et al, in press). A further example for a
recent founder effect in the Swiss population is the high incidence
(approximately 5%) of the cystic ®brosis transmembrane con-
ductance regulator (CFTR) gene mutation insT3905 among
patients with cystic ®brosis, as evidenced by its association with a
conserved haplotype of three highly polymorphic intragenic
microsatellites (Hergersberg et al, 1997). It is therefore tempting
to speculate that the Swiss population is at least partly constituted
from relatively homogeneous subpopulations.
As shown in this study, the utilization of intragenic SNP in the
FECH gene played a decisive role in the search for ancestral
founders of various mutations. Our results supported the view that
SNP, due to their low mutation rates, are appropriate markers for
the identi®cation of founder haplotypes. Using extragenic micro-
satellite markers, Wang and colleagues studied haplotypes of EPP
patients from unrelated families carrying identical FECH gene
mutations commonly found in the U.S.A. (Wang et al, 1999). The
questions raised from their study as to whether the two common
mutations were ``hotspots'' or ``dispersed ancestral mutant alleles''
in the FECH gene might be clari®ed by the analysis of the
intragenic SNP haplotypes.
The hereditary mode of EPP has long been a discussion point.
The description ``an autosomal dominant disorder with a low
Table II. Haplotypes of the nonmutant FECH alleles
among patients of EPP families
Locus
Family
I II IV III V VI VII
D18S69 4 3 6 3 3 6 5
D18S1152 5 5 3 6 1,4 3 3
D18S41 4 2 3 4 2 4 2
D18S858 5 4 5 5 3 3 4
±251 A/G G G G G G G A
IVS1-23 C/T T T T T T T C
798 G/C C C C CG C G G
921 G/A AG A A G G G G
1520 C/T C C C T T T C
D18S381 6 6 6 4 4 6 2
D18S977 2,6 2 4 2 2 3 2
D18S1144 12 10 10 7,12 5 12 3
D18S1155 1 1,4 4 3 3 1 1
D18S64 2 5 5 3 3,4 5 4
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clinical penetrance'' has been the most commonly used term in
EPP, although in some respects the disease resembles an autosomal
recessive disorder. Based on clinical and biochemical analyses of
over 200 EPP patients, Went and Klasen proposed a ``third allele''
hypothesis to explain the low clinical penetrance in EPP (Went and
Klasen, 1984). In this hypothesis, an unknown factor or a ``third
allele'' in addition to the defective enzyme was postulated to be
responsible for the clinical manifestation of EPP. The hypothetical
``third allele'' was substantiated through the identi®cation of a low
expressed FECH allele in a number of EPP families (Gouya et al,
1996, 1999). Hence, the full expression of EPP phenotype requires
the coinheritance of a ``normal'' FECH allele that has low
expression and a mutant FECH allele (Gouya et al, 1999).
The extensive genetic information gathered in this study enabled
us to verify Gouya's latest ®ndings. As seen in all pedigrees, a
disease-precipitating nonmutant allele cosegregated with the
mutant FECH allele in patients. These nonmutant, presumably
low expressed, alleles were characterized by an SNP haplotype [±
251G; IVS1±23T] in six out of seven families. With the exception
of the two SNP, no other common features, either intragenic or
extragenic, were observed among the nonmutant alleles in all seven
EPP pedigrees.
Undoubtedly, the [±251G; IVS1±23T] haplotype is strongly
linked to the low expressed FECH allele, as Gouya et al concluded
in their studies, as the same haplotype was identi®ed in the low
expressed normal FECH alleles from the six French EPP families
tested (Gouya et al, 1996, 1999). We did ®nd an exception of a
nonmutant FECH allele carrying [±251 A; IVS1±23C] in one
pedigree (family VII), however. Interestingly, although the index
patient in this family suffers from typical clinical symptoms of EPP,
the mother of the index patient, now aged 74, used to be
symptomatic until the age of 35.
Except for the fact that the low expressed FECH allele has a
reduced mRNA output, little is known about the mechanism of
low expression. The role of SNP ±251 A/G on the transcriptional
activity of FECH was recently examined by Magness et al (2000).
Two FECH promoters of 1.1 kb, one with an A and the other with
a G at position ±251, were cloned separately in front of a reporter
gene. No differences in terms of the amount of protein generated
by the reporter gene were observed between the two promoters.
The C®T transition at position ±23 in intron 1 can indeed cause
the skipping of exon 2 as observed by Nakahashi et al (1992). IVS1±
23T, however, by way of exon 2 skipping, is certainly not the only
explanation for the low mRNA output as, at least in family VII, the
EPP patient was homozygous C/C at IVS1±23. The continuing
search for a functional mutation in the low expressed FECH allele
may eventually lead to the clari®cation of the low expression
mechanism in EPP.
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